» Articles » PMID: 20871783

Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns

Abstract

Clear cell renal cell carcinoma (ccRCC) is the predominant RCC subtype, but even within this classification, the natural history is heterogeneous and difficult to predict. A sophisticated understanding of the molecular features most discriminatory for the underlying tumor heterogeneity should be predicated on identifiable and biologically meaningful patterns of gene expression. Gene expression microarray data were analyzed using software that implements iterative unsupervised consensus clustering algorithms to identify the optimal molecular subclasses, without clinical or other classifying information. ConsensusCluster analysis identified two distinct subtypes of ccRCC within the training set, designated clear cell type A (ccA) and B (ccB). Based on the core tumors, or most well-defined arrays, in each subtype, logical analysis of data (LAD) defined a small, highly predictive gene set that could then be used to classify additional tumors individually. The subclasses were corroborated in a validation data set of 177 tumors and analyzed for clinical outcome. Based on individual tumor assignment, tumors designated ccA have markedly improved disease-specific survival compared to ccB (median survival of 8.6 vs 2.0 years, P = 0.002). Analyzed by both univariate and multivariate analysis, the classification schema was independently associated with survival. Using patterns of gene expression based on a defined gene set, ccRCC was classified into two robust subclasses based on inherent molecular features that ultimately correspond to marked differences in clinical outcome. This classification schema thus provides a molecular stratification applicable to individual tumors that has implications to influence treatment decisions, define biological mechanisms involved in ccRCC tumor progression, and direct future drug discovery.

Citing Articles

Construction of a prognostic risk model for clear cell renal cell carcinomas based on centrosome amplification-related genes.

Zhou B, Liu F, Wan Y, Luo L, Ye Z, He J Mol Genet Genomics. 2025; 300(1):30.

PMID: 40075035 PMC: 11903526. DOI: 10.1007/s00438-025-02237-7.


Immune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas.

Miller J, Johnson J, Guske C, Mannam G, Hatoum F, Nassar M Cancers (Basel). 2025; 17(2).

PMID: 39858107 PMC: 11763753. DOI: 10.3390/cancers17020326.


Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma.

Oosterwijk-Wakka J, Houkes L, van der Zanden L, Kiemeney L, Junker K, Warren A Neoplasia. 2024; 60:101108.

PMID: 39724752 PMC: 11732189. DOI: 10.1016/j.neo.2024.101108.


Screening of differential gene expression patterns through survival analysis for diagnosis, prognosis and therapies of clear cell renal cell carcinoma.

Ajadee A, Mahmud S, Hossain M, Ahmmed R, Ali M, Reza M PLoS One. 2024; 19(9):e0310843.

PMID: 39348357 PMC: 11441673. DOI: 10.1371/journal.pone.0310843.


Long-read RNA sequencing of archival tissues reveals novel genes and transcripts associated with clear cell renal cell carcinoma recurrence and immune evasion.

Lee J, Snell E, Brown J, Booth C, Banks R, Turner D Genome Res. 2024; 34(11):1849-1864.

PMID: 39284687 PMC: 11610457. DOI: 10.1101/gr.278801.123.


References
1.
Nogueira M, Kim H . Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol. 2008; 26(2):113-24. DOI: 10.1016/j.urolonc.2007.03.028. View

2.
Alexe G, Dalgin G, Scanfeld D, Tamayo P, Mesirov J, DeLisi C . High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 2007; 67(22):10669-76. DOI: 10.1158/0008-5472.CAN-07-0539. View

3.
Gordan J, Lal P, Dondeti V, Letrero R, Parekh K, Oquendo C . HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008; 14(6):435-46. PMC: 2621440. DOI: 10.1016/j.ccr.2008.10.016. View

4.
Lam J, Shvarts O, Leppert J, Pantuck A, Figlin R, Belldegrun A . Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005; 174(2):466-72. DOI: 10.1097/01.ju.0000165572.38887.da. View

5.
Takahashi M, Rhodes D, Furge K, Kanayama H, Kagawa S, Haab B . Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A. 2001; 98(17):9754-9. PMC: 55525. DOI: 10.1073/pnas.171209998. View